These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37906680)

  • 1. Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Jeng WJ; Chien RN; Liaw YF
    Hepatology; 2024 Apr; 79(4):E109-E110. PubMed ID: 37906680
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Deng R; Wang Z; Liu Y; Sun J
    Hepatology; 2024 Apr; 79(4):E107-E108. PubMed ID: 37906598
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Jeng WJ; Chien RN; Liaw YF
    Hepatology; 2024 May; 79(5):E134-E135. PubMed ID: 38150032
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
    Liaw YF; Jeng WJ; Chien RN
    Hepatology; 2024 Mar; 79(3):E97-E98. PubMed ID: 37862454
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
    Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
    J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history and prognosis of hepatitis B.
    Fattovich G
    Semin Liver Dis; 2003 Feb; 23(1):47-58. PubMed ID: 12616450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
    Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
    Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    J Hepatol; 2021 Dec; 75(6):1495-1496. PubMed ID: 34171438
    [No Abstract]   [Full Text] [Related]  

  • 13. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
    Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
    Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
    Cheng DY; Zhao ZM; Wan G; Zheng HW; Huang JQ; Liu CH; Xing HC
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):479-484. PubMed ID: 35346577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
    Ma H; Guo F; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1832-5. PubMed ID: 17922993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients.
    Peng CW; Jeng WJ
    Hepatol Int; 2021 Apr; 15(2):527-528. PubMed ID: 33904110
    [No Abstract]   [Full Text] [Related]  

  • 18. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
    Buster EH; Hansen BE; Buti M; Delwaide J; Niederau C; Michielsen PP; Flisiak R; Zondervan PE; Schalm SW; Janssen HL;
    Hepatology; 2007 Aug; 46(2):388-94. PubMed ID: 17604363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.